API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/biohaven-completes-enrollment-of-verdiperstat-arm-of-pivotal-healey-als-platform-trial-conducted-by-the-healey-center-for-als-at-massachussetts-general-hospital-301423211.html
https://www.reuters.com/business/healthcare-pharmaceuticals/biohavens-drug-candidate-neurological-disorder-fails-study-2021-09-27/
https://www.biohavenpharma.com/investors/news-events/press-releases/08-03-2020
https://www.prnewswire.com/news-releases/biohaven-completes-enrollment-ahead-of-timelines-in-international-phase-3-clinical-trial-of-verdiperstat-in-multiple-system-atrophy-301096602.html
https://www.prnewswire.com/news-releases/biohavens-verdiperstat-receives-fast-track-designation-for-the-treatment-of-multiple-system-atrophy-301025830.html
https://www.prnewswire.com/news-releases/biohaven-enrolls-first-patient-in-phase-3-clinical-trial-of-verdiperstat-oral-myeloperoxidase-inhibitor-for-the-treatment-of-multiple-system-atrophy-300893543.html
https://www.prnewswire.com/news-releases/biohavens-verdiperstat-receives-orphan-drug-designation-from-fda-for-multiple-system-atrophy-300797627.html
https://www.fiercebiotech.com/biotech/biohaven-picks-up-astrazeneca-cns-drug-plans-phase-3
https://www.fiercebiotech.com/biotech/after-rare-disease-failure-biohaven-pushes-gas-oral-migraine-drug